Legend Biotech Corporation is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. The company's lead product, ciltacabtagene autoleucel (marketed as CARVYKTI), is an autologous CAR-T cell therapy targeting the BCMA protein for the treatment of multiple myeloma. Legend Biotech operates through subsidiaries in the United States, China, and the European Union, where it maintains principal manufacturing and research and development facilities. The company collaborates with strategic partner Janssen to co-develop and commercialize cilta-cel. Regulatory approvals for CARVYKTI have been granted by the FDA, the European Commission, Japan’s Ministry of Health, Labour and Welfare, and China’s NMPA. The company’s pipeline includes next-generation cell therapies across autologous, allogeneic, and in vivo platforms, with clinical trials evaluating cilta-cel in earlier lines of therapy for multiple myeloma and other hematologic malignancies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage legendbiotech.com
Sector Healthcare IR page investors.legendbiotech.com
Tags
cell therapy, car-t, oncology, multiple myeloma, hematologic malignancies, autologous, allogeneic, in vivo, bcma, nanobodies, CARVYKTI, ciltacabtagene autoleucel, cilta-cel, LCAR-B38M, Janssen, Janssen Biotech Inc., LEGEND-2, CARTIFAN-1, CARTITUDE-2, CARTITUDE-4, CARTITUDE-5, CARTITUDE-6, European Myeloma Network
Press page —

Metrics

Valuation  
Market cap $ 3.981B
Market cap (USD) $ 3.981B
P/E —
PEG —
P/BV 3.13
P/S 3.87
P/OCF -39.73
P/FCF -30.91
Dividend yield —
Turnover / mcap —
Returns  
ROE -29.1%
ROI -22.5%
ROIC -7.7%
Profit margin -28.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 75
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 1.029B 627.241M 285.143M 117.005M 89.792M 75.676M 57.264M
Net profit -296.8M -177.026M -518.254M -446.349M -386.209M -303.477M -132.972M
Free cash flow -128.8M -158.138M -413.36M -222.208M -242.37M -268.752M -121.701M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 21.74 32.54 60.17 49.92 46.61 28.16 —
Price performance 12m -0.33 -0.46 0.21 0.07 0.66 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 60.6M 162M 232M 313M 336M 382M 414M 415M
↳ 5y CAGR +44.5% +20.6% +12.3%
Reported Apr 2, 2021 Apr 2, 2021 Apr 2, 2021 Mar 31, 2022 Mar 30, 2023 Mar 19, 2024 Mar 11, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million

•Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI® infusion, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM

•Updated NCCN Guidelines recommend that all patients with multiple myeloma be referred to a T-cell therapy capable center at first relapse for consideration of available therapies

•Received U.S. FDA IND clearance for LB2501, an investigational CD19/CD20 dual-targeting in vivo CAR‑T therapy for relapsed or refractory B-cell malignancies

•Appointed Ingrid Zhang as Chief Executive Officer

•Cash and cash equivalents, and time deposits of approximately $853 million, as of September 30, 2026

Bridgewater, N.J.—November 10, 2026— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2026 unaudited financial results and recent highlights.

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment

Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells

BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were accepted for the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12–15 in New Orleans, Louisiana. The presentations will highlight new clinical and real-world analyses of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in multiple myeloma, as well as updated data from Legend Biotech’s next-generation cell therapy programs. The program includes two oral presentations, four posters, and an additional ePublication.

The CARVYKTI presentations include new analyses from the CARTITUDE-4 study providing additional insights into outcomes in earlier-line treatment, as well as real-world safety and efficacy outcomes in this setting.

Oct 27, 2026

PDF Version

BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.

During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.

Investors and other interested parties may access the live audio webcast via this weblink.

A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT: Caroline Paul Tel: (973) 650-5832 [email protected]

PRESS CONTACT: Kim Fox Tel: (848) 388-8445 [email protected]

Primary Logo

close

You are about to leave Investors.LegendBiotech.com

PROCEED KEEP ME HERE

Legend Biotech Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

Some Cookies are strictly necessary to make our Services available to you and you cannot use them without this type of Cookie. We use this information to provide you with our Services, prevent misuse, and ensure our Services are working properly.

Performance Cookies

Performance Cookies

These Cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information that these Cookies collect is aggregated and therefore anonymous. If you do not allow these Cookies, we will not know when you have visited our site and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Statistical/Analytical

Statistical/Analytical

These cookies are used for analytics purposes to better understand how you use our Services and how you navigate our website, to measure the effectiveness of our customer communications, to diagnose and fix technology problems, and otherwise enhance our Services.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Prompts

Legend Biotech Corporation (ticker LEGN), listed in United States.

ETFs Holding Legend Biotech Corporation

ETF Weight in ETF Shares Market value As of
MEMS 3.23% 25,297 $ 730.577K Jun 30, 2026
EMSF 2.16% 35,976 $ 1.039M Jun 30, 2026
CANC 1.95% 197,934 $ 4.113M Aug 31, 2026
FMED 1.45% 36,000 $ 748.08K Aug 31, 2026
MEDI 1.00% 24,327 $ 451.023K Nov 12, 2026
PINK 0.90% 186,947 $ 3.012M Nov 17, 2026
GPT 0.33% 2,700 $ 77.976K Jun 30, 2026
JDOC 0.25% 1,539 $ 24.793K Nov 17, 2026
MSSM 0.22% 75,207 $ 1.563M Aug 31, 2026
AVEE 0.13% 10,315 $ 164.937K Nov 16, 2026
FBCG 0.02% 68,015 $ 1.262M Jul 31, 2026
APIE 0.00% 1,771 $ 36.801K Aug 31, 2026
AVEM 0.00% 29,667 $ 474.375K Nov 16, 2026
CORO 0.00% 14,755 $ 235.929K Nov 16, 2026